With Black women and straight men increasingly at risk, Gilead’s Yeztugo may finally offer a discreet, stigma-free way to ...

Similarly, Gilead has provided nearly $35.8 million in total philanthropic support for Black women-led and/or Black ...

2. Learn the facts and be prepared. Get informed about HIV and how to prevent being infected. Pass out condoms to your friends and family to remind them to be safe the next time they decide to have ...

A new study explores how healthcare providers can effectively implement Apretude for HIV pre-exposure prophylaxis (PrEP) among Black cisgender and transgender women. A new study presented at the ...

By: Dr. Vani C, Consultant Microbiologist, Metropolis Healthcare Ltd., Bengaluru In the ongoing global fight against HIV/AIDS, regular testing and early diagnosis play a pivotal role.

The Food and Drug Administration has approved a new injectable drug that can help prevent HIV. Dr. Amesh Adalja, a senior scholar at the Johns Hopkins University Center for Health Security, joins ...

Rael and Stonbraker said they had secured about $1 million focused on HIV prevention mostly among transgender people, like one study to help recruit transgender people for HIV vaccine trials.

The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that could protect millions – although it’s unclear how many in the U.… ...

Twice-a-year shot to prevent HIV could stop transmission — if people can get it Wednesday’s FDA approval marks the first step in an anticipated global rollout that experts say could protect ...

While a vaccine to prevent HIV still is needed, some experts say the shot made by Gilead Sciences — a drug called lenacapavir — could be the next best thing.

Twice-a-year shot to prevent HIV could stop transmission — if people can get it Tests found that new drug nearly eliminated new infections. By The Associated Press Wire Service Jun. 18, 2025 ...

The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that could protect millions – although it's unclear how many in the U.S ...